Medinox - Company Information on Medinox

Press Enter or Click Search to perform a full site search.

Company Name Matches

Show All Search Results »

Companies>Medinox

Add to Watch List Share This Page

Email Page Flag This Page

Flag

Headline: Good Health is Our Business

Website: http://www.medinox.com/

Medinox, Inc. is a San Diego-based pharmaceutical company that is developing new small molecule drugs to treat a wide variety of unmet medical needs including sepsis, arthritis & inflammation, diabetes and sickle cell anemia.

The Company's research and clinical development programs fall into two broad categories:
Nitric oxide neutralizers

* NOX-100 - injectable compound for septic...More»

Address: 6120 Paseo Del Norte Suite B-2 Carlsbad, CA 92009 Map it »

Phone: 760-603-8989

Email: info@medinox.com

Founded: 05/01/1995

Industry: Biopharmaceuticals

Sub-Industry: Pharmaceuticals

Legal Structure: Corporation

Ownership: Private

Management

Board of Directors

Advisors

Date	Type	Capital Amount	Post-Money Valuation	Investors
01/2002	Series B	13.8M	Unknown	China Development Industrial Bank, Industrial Bank of Taiwan, Chiao Tung Bank Co., Ltd., CIH Investment Capital Limited, Core Pacific Venture Capital, Hua Hsia Investment Holding Co., IBT Venture Co., Taiwan Biotech Co., Ltd., Prudence Venture Investment Corporation

Name:	Nitric Oxide Neutralizers
Product URL:	http://www.medinox.com/home/technology/index.html
Description:	Nitric oxide (NO), is a simple gaseous free radical that plays a dual role in human health and disease. In small amounts, NO is an essential physiological regulator, playing important roles in blood pressure regulation, memory, and host defense. On the other hand, NO overproduction, which is a feature common to many medical problems and disorders, causes molecular damage that leads to disease-causing cellular dysfunction. To address this dual role, Medinox is developing its proprietary NO neutralizers, a unique pharmaceutical technology that removes the excess pathology-causing NO while preserving the basal beneficial levels of NO. Our small-molecule NO neutralizers bind nitric oxide very tightly and with great specificity. The bound NO is thus inactivated and prevented from participating in pathology-causing reactions. Both injectable and orally-active NO neutralizers are under development. Targeted diseases and disorders include sepsis, ARDS and diabetes, among many others. Medinox's most advanced product, the injectable NO neutralizer NOX-100, which was shown to have an excellent safety profile in a recent human study. NOX-100 is now being evaluated in a multicenter Phase I/IIa septic shock study.